Literature DB >> 27503570

Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.

Stephen M Stahl.   

Abstract

Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27503570     DOI： 10.1017/S1092852916000407

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  14 in total

Review 1.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

Review 2.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

Review 3.  Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.

Authors:  Mehnaz Ahmed; Marlene Malik; Johannes Teselink; Krista L Lanctôt; Nathan Herrmann
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 4.  "Selective" serotonin 5-HT2A receptor antagonists.

Authors:  Austen B Casey; Meng Cui; Raymond G Booth; Clinton E Canal
Journal:  Biochem Pharmacol       Date:  2022-04-04       Impact factor: 6.100

Review 5.  Hallucinations in Healthy Older Adults: An Overview of the Literature and Perspectives for Future Research.

Authors:  Johanna C Badcock; Hedwige Dehon; Frank Larøi
Journal:  Front Psychol       Date:  2017-07-07

6.  Treatment of psychotic symptoms in patients with Parkinson disease.

Authors:  Jack J Chen
Journal:  Ment Health Clin       Date:  2018-03-23

Review 7.  Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Authors:  Fabio Del Bello; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia
Journal:  Biomolecules       Date:  2019-04-09

Review 8.  Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.

Authors:  Holly Green; Panagiota Tsitsi; Ioanna Markaki; Dag Aarsland; Per Svenningsson
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

9.  Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature.

Authors:  Katie T B Touma; Daniel C Touma
Journal:  Ment Health Clin       Date:  2018-03-23

Review 10.  Relevance of 5-HT2A Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy.

Authors:  Ethan S Burstein
Journal:  CNS Drugs       Date:  2021-07-05       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.